<DOC>
	<DOCNO>NCT01107457</DOCNO>
	<brief_summary>The primary purpose study help answer follow research question - The safety ixekizumab ( LY2439821 ) side effect might associate . - Whether ixekizumab help participant Psoriasis . - How much ixekizumab give participant .</brief_summary>
	<brief_title>A Study Participants With Moderate Severe Psoriasis</brief_title>
	<detailed_description>The study Phase 2 study 2 part . Part A randomized , double-blind , placebo-controlled , parallel-group , dose-ranging design Part B optional , open label extension design . Approximately 125 participant randomize 1 4 ixekizumab group placebo ( approximately 25 participant per group ) Part A . Participants evaluate treatment efficacy primary endpoint evaluate week 12 . Between week 20 week 32 , participant le 75 % improvement Psoriasis Area Severity Index ( PASI ) score compare baseline eligible begin Part B . Participants Part B receive subcutaneous ( SC ) injection ixekizumab 120 milligram ( mg ) every 4 week week 236 . Subsequent amendment May 2012 , administration change 80 mg every 4 week Week 236 . Participants complete Part A B total study participation approximately 240 264 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion Criteria Common Both Part A B : You must active plaque psoriasis cover least 10 % body surface area PASI score 12 You candidate systemic therapy You sPGA score least 3 screen randomization Inclusion Criterion Specific Part B You complete treatment period part A ( week 20 ) Exclusion Criteria Common Both Part A B : You pustular , erythrodermic and/or guttate form psoriasis You clinically significant flare psoriasis 12 week prior study entry You recently use biologic agent/monoclonal antibody within follow washout period : etanercept &gt; 28 day , infliximab adalimumab &gt; 56 day , alefacept &gt; 60 day , ustekinumab &gt; 8 month , biologic agent/monoclonal antibody &gt; 5 halflives prior baseline You receive systemic psoriasis therapy ( psoralen ultraviolet A [ PUVA ] light therapy , cyclosporine , corticosteroid , methotrexate , oral retinoids , mycophenolate mofetil , thioguanine , hydroxyurea , sirolimus , azathioprine ) phototherapy ( include ultraviolet B selftreatment tan bed ) within previous 4 week ; topical psoriasis treatment within previous 2 week prior randomization ( exception : class 6 [ mild , desonide ] 7 [ least potent , hydrocortisone ] topical steroid permit use limited face , axilla , and/or genitalia ) You donate 500 mL blood within last month You another serious disorder illness You suffer serious bacterial infection ( example , pneumonia , cellulitis ) within last 3 month You history uncontrolled high blood pressure You clinical laboratory test result entry outside normal reference range You currently participate discontinue within last 30 day another clinical trial involve investigational drug You woman lactate breast feeding If woman could become pregnant study , must talk study doctor birth control use avoid get pregnant study If post menopausal woman , must least 45 year age menstruate last 12 month If woman 4045 year age , test negative pregnancy , menstruate last 12 month , must additional blood test see participate If male , must agree reduce risk female partner become pregnant study Exclusion Criteria Specific B : If experience Serious Adverse Event Part A consider possibly relate ixekizumab If experienced Adverse Event Part A study doctor believe ixekizumab treatment could cause harm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Moderate</keyword>
	<keyword>Severe</keyword>
	<keyword>Plaque</keyword>
	<keyword>Chronic</keyword>
</DOC>